首页> 外国专利> Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands

Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligands

机译:抑制B7-1和B7-2与其天然配体相互作用的治疗组合物

摘要

Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO:1 or FIG. 14, SEQ ID NO:23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.
机译:公开了编码新的CTLA4 / CD28配体的核酸,其共刺激T细胞活化。在一个实施方案中,核酸具有编码B淋巴细胞抗原B7-2的序列。优选地,核酸是包含图1所示的核苷酸序列的至少一部分的DNA分子。 8 ,SEQ ID NO:1或图2。 14 ,SEQ ID NO:23。可以将本发明的核酸序列整合到各种表达载体中,所述表达载体继而指导相应的蛋白质或肽在各种宿主,特别是真核细胞,例如哺乳动物和昆虫细胞培养物中的合成。还公开了被转化以产生由本发明的核酸序列编码的蛋白质或肽的宿主细胞以及包含至少一部分新的B淋巴细胞抗原的分离的蛋白质和肽。可将本文所述的蛋白质和肽施用于受试者以增强或抑制T细胞介导的免疫反应。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号